secwatch / observer
8-K filed May 6, 2026, 7:59 PM ET ticker WES CIK 0001423902
other material confidence high sentiment positive materiality 0.85

WES Q1 adj EBITDA record $683M; acquires Brazos Delaware for $1.6B

Western Midstream Partners, LP

item 2.02item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001423902-26-000043
form_type
8-K
ticker
WES
cik
0001423902
company_name
Western Midstream Partners, LP
filed_at
2026-05-06T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.266666+00:00
generated_at
2026-05-14T22:35:38.470484+00:00
sec_items
["2.02", "7.01", "9.01"]
event_type
other_material
sentiment
positive
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001423902-26-000043
json_url
https://secwatch.observer/filing/0001423902-26-000043.json
markdown_url
https://secwatch.observer/filing/0001423902-26-000043.md
text_url
https://secwatch.observer/filing/0001423902-26-000043.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1423902/000142390226000043/0001423902-26-000043-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1423902/000142390226000043/wes-20260506.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

10959353b17d55c6ab502328c518a9b255e0590e

Western Midstream Partners, LP reported first-quarter 2026 results: net income $342.4 million, EPS $0.85 per common unit (diluted).

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

ARTV

Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M

Artiva Biotherapeutics, Inc. May 8, 2026, 7:59 PM ET other_material Items 2.02, 7.01, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 same event type: other_material similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

Artiva Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.

Filing page SEC filing

VSCO

Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook

Victoria's Secret & Co. June 2, 2026, 7:01 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.

Filing page SEC filing

DG

Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance

DOLLAR GENERAL CORP June 2, 2026, 6:54 AM ET earnings Items 2.02, 5.07, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026 Highlights · Net Sales Increased 3.4% to $10.8 Billion · Same-Store Sales Increased 2.0% · Operating Profit Increased 10.8% to $638.5 Million · Diluted Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash Flow From

Filing page SEC filing

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

ACH

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

ACCENDRA HEALTH INC/VA/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

Commission this morning. ​ Details on First Quarter 2026 Results ​ ​ First Quarter Results (1) ​ ($ in millions, except per share data) ​ ​ ​ 1Q26 ​ ​ ​ 1Q25 Net Revenue ​ $ 627.8 ​ $ 673.9 ​ ​ ​ ​ ​ ​ ​ Loss from continuing operations, net of tax, GAAP ​ $ (6.5) ​ $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP ​ $ (3.1) ​ $ 23.2 ​ ​ ​

Filing page SEC filing

FSK

FSK posts Q1 GAAP loss of $1.57/sh, NAV falls to $18.83; announces $150M preferred, tender, buyback

FS KKR Capital Corp May 11, 2026, 7:59 PM ET earnings Items 1.01, 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

Earnings (Loss) per share of ($1.57), compared to Earnings (Loss) per share of ($0.41) for the quarter ended December 31, 2025

Filing page SEC filing

SBET

Sharplink Q1 revenue $12.1M, net loss $685.6M; plans $125M Galaxy Onchain Yield Fund

Sharplink, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

First Quarter 2026 Highlights Income Statement and Balance Sheet ● Total revenue increased materially to $12.1 million in Q1 2026, compared to $0.7 million for the three months ended March 31, 2025. The increase was primarily driven by the continued success of Sharplink’s actively managed ETH treasury strategy, which was launched on June 2, 2025. ● SG&A expenses were $9.9 million for the three months ended March 31, 2026, compared to $1.1 million in the prior year’s first quarter. The increase was primarily due to expenditures for investments in infrastructure, talent and systems required to scale and actively manage Sharplink’s institutional-grade ETH treasury platform. ● Net loss was $685.6 million in Q1 2026, compared to $1.0 million for the three months ended March 31, 2025.

Filing page SEC filing

MLTX

MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M

MoonLake Immunotherapeutics May 11, 2026, 7:59 PM ET regulatory Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 7.01, 9.01 similar materiality

This filing

Net income (loss) attributable to limited partners for the first quarter of 2026 totaled $342.4 million, or $0.85 per common unit (diluted)

Comparable filing

Today, MoonLake also reported its financial results for the first quarter of 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001423902-26-000043
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.